Protalix BioTherapeutics (PLX) Misses Q2 EPS by 3c
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q2 EPS of ($0.03). Revenue for the quarter came in at $13.47 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Opera Limited (OPRA) Misses Q2 EPS by 1c ; Offers Guidance
- Wedbush Starts Aktis Oncology (AKTS) at Outperform
- Hyperscale Data declares preferred stock dividends for September
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
